发明名称 |
Compositions and methods for treating bone conditions |
摘要 |
A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells. |
申请公布号 |
US9289467(B2) |
申请公布日期 |
2016.03.22 |
申请号 |
US201213572141 |
申请日期 |
2012.08.10 |
申请人 |
Case Western Reserve University |
发明人 |
Lin Feng;Dennis James E.;Tu Zhidan |
分类号 |
A61K39/00;A61K39/395;A61K38/17;A61K31/7088;A61K31/713;C07K16/18 |
主分类号 |
A61K39/00 |
代理机构 |
Tarolli, Sundheim, Covell & Tummino LLP |
代理人 |
Tarolli, Sundheim, Covell & Tummino LLP |
主权项 |
1. A method of treating a degenerative bone condition in a subject in need thereof, the method comprising:
administering locally to hematopoietic progenitor cells or osteoclast progenitor cells a C3a receptor (C3aR) antagonist directed against C3aR, the C3aR antagonist being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of the hematopoietic progenitor cells or osteoclast progenitor cells, the hematopoietic progenitor cells or osteoclast progenitor cells being in the subject or administered to the subject. |
地址 |
Cleveland OH US |